Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients

Sponsor
Mansoura University
Study ID
NCT06897605
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Anemia, Kidney Disease, Chronic
  • Chronic Kidney Disease(CKD)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin (DAPA) — DRUG
    Dapagliflizin 10 mg tablets once daily for 12 weeks
  • Erythropoiesis Stimulating Agent — DRUG
    Erythropoiesis stimulating agent (ESA) therapy

Study Details

Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, primarily used in the management of type 2 diabetes mellitus. Emerging research suggests that SGLT2 inhibitors may offer additional benefits, including reducing the risk of cardiovascular events and renal complications. Post hoc analyses of previous clinical trials have shown that patients treated with SGLT2 inhibitors exhibited higher levels of hemoglobin and hematocrit compared to those in the control group. These findings suggest that dapagliflozin's ability to elevate hemoglobin levels could potentially be utilized for the treatment of anemia in patients with chronic kidney disease.

Key Dates

Start date
Apr 1, 2025
Status verified
Mar 2025
Primary completion
Oct 31, 2025
Completion
Oct 31, 2025

Study Design

Enrollment
80 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Dapagliflozin + ESA group
    patients will receive dapagliflozin 10 mg tablet once daily in addition to standard care therapy of erythropoiesis-stimulating agents (ESA)
  • Other: Control group
    patients will receive standard care therapy of erythropoiesis-stimulating agents (ESA)

Primary Outcome Measure

Change in Erythropoiesis stimulating agent therapy dose [ Time Frame: 12 weeks ]

Central Contacts

Related Studies